Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804478 | 1.00 | MAPK8 (0.46) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1797203 | 0.97 | MAPK8 (0.49) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1797206 | 0.97 | MAPK8 (0.49) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1799310 | 0.84 | MAPK8 (0.44) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1799309 | 0.84 | MAPK8 (0.44) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1795043 | 0.83 | MAPK8 (0.43) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1795045 | 0.83 | MAPK8 (0.43) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1799514 | 0.82 | MAPK8 (0.44) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1799516 | 0.82 | MAPK8 (0.44) | MAPK8MAPK9MAPK10IRAK4ACVR1 | |
| SCHEMBL1801905 | 0.81 | MAPK8 (0.47) | MAPK8MAPK9MAPK10IRAK4ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | MAPK8 33/4885MAPK9 27/4885MAPK10 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.